Canada markets closed
LATEST UPDATE

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

We are taking a short break, but we will be back next week. Stay tuned!

ORTX Oct 2021 5.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.85000.0000 (0.00%)
At close: 11:38AM EDT
Full screen
Previous Close2.8500
Open2.8500
Bid2.6500
Ask2.9500
Strike5.00
Expire Date2021-10-15
Day's Range2.8500 - 2.8500
Contract RangeN/A
Volume1
Open Interest2
  • GlobeNewswire

    Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress

    Nine accepted abstracts demonstrate broad potential of the company’s HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disordersBOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22. Clinical and pre-clinical data from across the com

  • GlobeNewswire

    Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

    Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present Opportunities for Future Partnerships BOSTON and LONDON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today will present on the company’s discovery and research efforts in hematopoietic stem cell (HSC) gene therapy, including an update on the OTL-104

  • GlobeNewswire

    Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

    Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today an